×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RAPP – rapport therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RAPP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/5
09:00 am
rapp
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
Medium
Report
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
11/28
12:07 pm
rapp
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? [Yahoo! Finance]
Low
Report
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? [Yahoo! Finance]
11/25
07:00 am
rapp
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
Low
Report
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
11/20
06:02 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Low
Report
Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
11/19
08:07 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) is now covered by analysts at BTIG Research. They set a "buy" rating and a $47.00 price target on the stock.
Medium
Report
Rapport Therapeutics (NASDAQ:RAPP) is now covered by analysts at BTIG Research. They set a "buy" rating and a $47.00 price target on the stock.
11/7
09:41 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) had its price target raised by analysts at Citizens Jmp from $77.00 to $80.00. They now have a "market outperform" rating on the stock.
Low
Report
Rapport Therapeutics (NASDAQ:RAPP) had its price target raised by analysts at Citizens Jmp from $77.00 to $80.00. They now have a "market outperform" rating on the stock.
11/7
05:30 am
rapp
Rapport Therapeutics, Inc.'s (NASDAQ:RAPP) latest 5.7% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
Low
Report
Rapport Therapeutics, Inc.'s (NASDAQ:RAPP) latest 5.7% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
11/6
07:00 am
rapp
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
Low
Report
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
07:00 am
RAPP
rapport therapeutics, inc.
BEAT
Report
-1.1%
rapport therapeutics, inc.
3/11/2025
07:00 am
RAPP
rapport therapeutics, inc.
BEAT
Report
9.0%
rapport therapeutics, inc.
3/11/2025
07:00 am
RAPP
rapport therapeutics, inc.
BEAT
Report
8.3%
rapport therapeutics, inc.
3/11/2025
07:00 am
RAPP
rapport therapeutics, inc.
BEAT
Report
11.7%
rapport therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/1
04:18 pm
rapp
Form 4 Rapport Therapeutics, For: Nov 26 Filed by: Gault Cheryl
Medium
Report
Form 4 Rapport Therapeutics, For: Nov 26 Filed by: Gault Cheryl
11/18
04:28 pm
rapp
Form 4 Rapport Therapeutics, For: Nov 17 Filed by: Ceesay Abraham
Medium
Report
Form 4 Rapport Therapeutics, For: Nov 17 Filed by: Ceesay Abraham
11/18
04:25 pm
rapp
Form 4 Rapport Therapeutics, For: Nov 17 Filed by: Bredt David
Medium
Report
Form 4 Rapport Therapeutics, For: Nov 17 Filed by: Bredt David
11/14
01:09 pm
rapp
Form SCHEDULE 13G/A Rapport Therapeutics, Filed by: Cormorant Asset Management, LP
Low
Report
Form SCHEDULE 13G/A Rapport Therapeutics, Filed by: Cormorant Asset Management, LP
11/6
07:31 am
rapp
Form 10-Q Rapport Therapeutics, For: Sep 30
Low
Report
Form 10-Q Rapport Therapeutics, For: Sep 30
11/6
07:15 am
rapp
Form 8-K Rapport Therapeutics, For: Nov 06
Low
Report
Form 8-K Rapport Therapeutics, For: Nov 06
10/22
05:09 pm
rapp
Form SCHEDULE 13G/A Rapport Therapeutics, Filed by: JOHNSON & JOHNSON
Medium
Report
Form SCHEDULE 13G/A Rapport Therapeutics, Filed by: JOHNSON & JOHNSON
10/16
04:30 pm
rapp
Form 4 Rapport Therapeutics, For: Oct 15 Filed by: Bredt David
Low
Report
Form 4 Rapport Therapeutics, For: Oct 15 Filed by: Bredt David
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: